Literature DB >> 27380051

[Perioperative coagulation management during ascending aorta replacement on apixaban].

C Dumps1, E Halbeck2, J Schimpf2, H Forst2.   

Abstract

The direct oral anticoagulants (DOACs) present a valid therapeutic alternative to vitamin K antagonists in patients with non-valvular atrial fibrillation, for the prevention of venous thromboembolism, and for the treatment and prevention of the recurrence of pulmonary embolisms and deep vein thrombosis. Despite Idarucizumab as an antagonist of Dabigatran there are no other specific antidotes available yet. Therefore, perioperative coagulation management by DOACs is challenging in patients undergoing emergency surgical procedures with a high risk of bleeding complications. This case study describes the perioperative procedure during ascending aorta replacement after aortic dissection with apixaban administration.

Entities:  

Keywords:  Antidotes; Aortic dissection; Ascending aortic replacement; Direct oral anticoagulants; Perioperative coagulation management

Mesh:

Substances:

Year:  2016        PMID: 27380051     DOI: 10.1007/s00101-016-0200-5

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  17 in total

Review 1.  Reversal of anticoagulants: an overview of current developments.

Authors:  Andreas Greinacher; Thomas Thiele; Kathleen Selleng
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

2.  [German Registry for Acute Aortic Dissection Type A (GERAADA): initial results].

Authors:  L O Conzelmann; T Krüger; I Hoffmann; B Rylski; J Easo; M Oezkur; K Kallenbach; O Dapunt; M Karck; E Weigang
Journal:  Herz       Date:  2011-09       Impact factor: 1.443

3.  Type A aortic dissection in a patient on dabigatran: hemostasis post circulatory arrest.

Authors:  Elena Ashikhmina; Nicole Tomasello; Jean Marie Connors; Jama Jahanyar; Michael Davidson; K Annette Mizuguchi
Journal:  Ann Thorac Surg       Date:  2014-12-01       Impact factor: 4.330

4.  Bleeding and the new anticoagulants: strategies and concerns.

Authors:  Charles Marc Samama; Jerrold H Levy
Journal:  Anesthesiology       Date:  2015-02       Impact factor: 7.892

5.  Aortic dissection during rivaroxaban therapy: a challenging care.

Authors:  J Béné; J L Auffray; M Auffret; J Caron; S Gautier
Journal:  Acta Anaesthesiol Scand       Date:  2014-11-14       Impact factor: 2.105

Review 6.  Management of acute aortic dissection.

Authors:  Christoph A Nienaber; Rachel E Clough
Journal:  Lancet       Date:  2015-02-06       Impact factor: 79.321

7.  The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease.

Authors:  P G Hagan; C A Nienaber; E M Isselbacher; D Bruckman; D J Karavite; P L Russman; A Evangelista; R Fattori; T Suzuki; J K Oh; A G Moore; J F Malouf; L A Pape; C Gaca; U Sechtem; S Lenferink; H J Deutsch; H Diedrichs; J Marcos y Robles; A Llovet; D Gilon; S K Das; W F Armstrong; G M Deeb; K A Eagle
Journal:  JAMA       Date:  2000-02-16       Impact factor: 56.272

Review 8.  Aortic dissections and dissecting aneurysms.

Authors:  C E Anagnostopoulos; M J Prabhakar; C F Kittle
Journal:  Am J Cardiol       Date:  1972-08       Impact factor: 2.778

9.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

10.  Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality.

Authors:  M J Unsworth-White; A Herriot; O Valencia; J Poloniecki; E E Smith; A J Murday; D J Parker; T Treasure
Journal:  Ann Thorac Surg       Date:  1995-03       Impact factor: 4.330

View more
  1 in total

1.  Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.

Authors:  Vítor Fagundes; Mari Mesquita
Journal:  Eur J Case Rep Intern Med       Date:  2019-12-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.